You are using an older browser version. Please use a supported version for the best MSN experience.

Panadol price hike not misleading: ACCC

AAP logoAAP 10/10/2016

The consumer watchdog says drug company GlaxoSmithKline was ambiguous but not misleading when it blamed federal government policy for hiking the price of its Panadol Osteo painkillers.

"There can be a fine line between an ambiguous statement and a misleading one," Australian Competition and Consumer Commission chairman Rod Sims said on Monday, finding there wasn't enough evidence to show the company contravened consumer laws.

Health Minister Sussan Ley asked the ACCC to investigate when the company said it would hike prices of Panadol Osteo following the government's decision to remove it from the Pharmaceutical Benefits Scheme from January 1, 2016.

image beaconimage beaconimage beacon